Fate Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 56 U.S.-traded ETFs. FATE has around 9.8M shares in the U.S. ETF market. The largest ETF holder of FATE is the ARK Genomic Revolution ETF (ARKG), with approximately 1.92M shares. Investors may also find of interest that the ETF with the largest allocation to FATE stock is Loncar Cancer Immunotherapy ETF (CNCR), with a portfolio weight of 5.06%. On average, U.S. ETFs allocate 0.66% of FATE to their portfolios.
Additionally, FATE is a favorite stock for Vanilla and Multi-factor ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with FATE as a holding is the ARK Genomic Revolution ETF (ARKG), with a return of 139.56%.